Cargando…

AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review

DESCRIPTION: The acute hepatic porphyrias (AHP) are rare, inborn errors of heme-metabolism and include acute intermittent porphyria, hereditary coproporphyria, variegate porphyria, and porphyria due to severe deficiency of 5-aminolevulinic acid dehydratase. Acute intermittent porphyria is the most c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Bruce, Bonkovsky, Herbert L., Lim, Joseph K., Balwani, Manisha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10335308/ https://www.ncbi.nlm.nih.gov/pubmed/36642627 http://dx.doi.org/10.1053/j.gastro.2022.11.034

Ejemplares similares

Acute Hepatic Porphyrias: Review and Recent Progress
por: Wang, Bruce, et al.
Publicado: (2018)

Elagolix is porphyrogenic and may induce porphyric attacks in patients with the acute hepatic porphyrias
por: Ma, Christopher D., et al.
Publicado: (2022)

Eslicarbazepine acetate is porphyrogenic and should be used with caution in patients with the acute hepatic porphyrias
por: Ma, Christopher D., et al.
Publicado: (2022)

AGA Clinical Practice Update on The Management of Refractory Helicobacter pylori Infection: Expert Review
por: Shah, Shailja C., et al.
Publicado: (2021)

Porphyrias in the Age of Targeted Therapies
por: Erwin, Angelika L., et al.
Publicado: (2021)

AGA Clinical Practice Update on Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: Expert Commentary
por: Rubin, David T., et al.
Publicado: (2020)

Pain in acute hepatic porphyrias: Updates on pathophysiology and management
por: Kazamel, Mohamed, et al.
Publicado: (2022)

Efficacy and safety of givosiran for acute hepatic porphyria: 24‐month interim analysis of the randomized phase 3 ENVISION study
por: Ventura, Paolo, et al.
Publicado: (2021)

Evaluating the Patient Reported Outcomes Measurement Information System Scales in Acute Intermittent Porphyria
por: Naik, Hetanshi, et al.
Publicado: (2019)

Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study
por: Wang, Bruce, et al.
Publicado: (2022)

Acute Hepatic Porphyria
por: Bissell, D. Montgomery, et al.
Publicado: (2015)

Benefits of prophylactic heme therapy in severe acute intermittent porphyria
por: Yarra, Pradeep, et al.
Publicado: (2019)

Spotlight on Givosiran as a Treatment Option for Adults with Acute Hepatic Porphyria: Design, Development, and Place in Therapy
por: Majeed, Chaudry Nasir, et al.
Publicado: (2022)

Idiosyncratic drug-induced liver injury caused by givosiran in a patient with acute intermittent porphyria
por: Ma, Christopher D., et al.
Publicado: (2022)

Recurrent symptoms of acute intermittent porphyria after biochemical normalization with givosiran—An ongoing clinical conundrum
por: Ma, Christopher D., et al.
Publicado: (2022)

An update of clinical management of acute intermittent porphyria
por: Pischik, Elena, et al.
Publicado: (2015)

Clinically Important Features of Porphyrin and Heme Metabolism and the Porphyrias
por: Besur, Siddesh, et al.
Publicado: (2014)

EXPLORE: A Prospective, Multinational, Natural History Study of Patients with Acute Hepatic Porphyria with Recurrent Attacks
por: Gouya, Laurent, et al.
Publicado: (2019)

Acute Intermittent Porphyria in Argentina: An Update
por: Cerbino, Gabriela Nora, et al.
Publicado: (2015)

EXPLORE B: A prospective, long‐term natural history study of patients with acute hepatic porphyria with chronic symptoms
por: Cassiman, David, et al.
Publicado: (2022)

Ledipasvir/Sofosbuvir Is Effective as Sole Treatment of Porphyria Cutanea Tarda with Chronic Hepatitis C
por: Bonkovsky, Herbert L., et al.
Publicado: (2023)

Acute hepatic porphyria and hepatocellular carcinoma.
por: Kauppinen, R., et al.
Publicado: (1988)

Endothelial Dysfunction in Acute Hepatic Porphyrias
por: Ricci, Andrea, et al.
Publicado: (2022)

Pathogenesis of acute encephalopathy in acute hepatic porphyria
por: Pischik, Elena, et al.
Publicado: (2023)

Porphyrin-Induced Protein Oxidation and Aggregation as a Mechanism of Porphyria-Associated Cell Injury
por: Maitra, Dhiman, et al.
Publicado: (2019)

Mechanisms of Neuronal Damage in Acute Hepatic Porphyrias
por: Ricci, Andrea, et al.
Publicado: (2021)

Challenges in diagnosis and management of acute hepatic porphyrias: from an uncommon pediatric onset to innovative treatments and perspectives
por: Marcacci, Matteo, et al.
Publicado: (2022)

Operative Treatment Options for Patellofemoral Arthritis: An Expert Recommendation of the AGA Patellofemoral Committee
por: Keshmiri, Armin, et al.
Publicado: (2021)

AGA-Mitteilungen
Publicado: (2020)

AGA-Mitteilungen
Publicado: (2020)

AGA-Mitteilungen
Publicado: (2020)

AGA-Mitteilungen
Publicado: (2021)

AGA Institute Quality Measure Development for the Diagnosis and Management of COVID-19
por: Leiman, David A., et al.
Publicado: (2021)

Acute Porphyria
por: Kernohan, R. J., et al.
Publicado: (1954)

Laboratory Diagnosis of Porphyria
por: Di Pierro, Elena, et al.
Publicado: (2021)

An Overview of Acute Hepatic Porphyrias: Clinical Implications, Diagnostic Approaches, and Management Strategies
por: Zübarioğlu, Tanyel, et al.
Publicado: (2023)

Variegate Porphyria Triggered by Acute Hepatitis A Infection
por: Micallef, Daniel, et al.
Publicado: (2020)

Acute Hepatic Porphyria: Pathophysiological Basis of Neuromuscular Manifestations
por: de Souza, Paulo Victor Sgobbi, et al.
Publicado: (2021)

Clinical features of Japanese patients with acute hepatic porphyria
por: Horie, Yutaka, et al.
Publicado: (2022)

Very Early Diagnosis and Management of Congenital Erythropoietic Porphyria
por: Desjardins, Marie-Pier, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_966etinmbq17pv9nscgcmnv27u